Skip to main content Accessibility help
×
Home

Trypanocidal drugs: mechanisms, resistance and new targets

  • Shane R. Wilkinson (a1) and John M. Kelly (a2)

Abstract

The protozoan parasites Trypanosoma brucei and Trypanosoma cruzi are the causative agents of African trypanosomiasis and Chagas disease, respectively. These are debilitating infections that exert a considerable health burden on some of the poorest people on the planet. Treatment of trypanosome infections is dependent on a small number of drugs that have limited efficacy and can cause severe side effects. Here, we review the properties of these drugs and describe new findings on their modes of action and the mechanisms by which resistance can arise. We further outline how a greater understanding of parasite biology is being exploited in the search for novel chemotherapeutic agents. This effort is being facilitated by new research networks that involve academic and biotechnology/pharmaceutical organisations, supported by public–private partnerships, and are bringing a new dynamism and purpose to the search for trypanocidal agents.

Copyright

Corresponding author

*Corresponding author: Shane Wilkinson, School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road, London, E1 4NS, UK. Tel: +44 (0)207 882 3057; Fax: +44 (0)20 8983 0973; E-mail: s.r.wilkinson@qmul.ac.uk

References

Hide All
1Steverding, D. (2008) The history of African trypanosomiasis. Parasites and Vectors 1, 3
2Barrett, M.P. et al. (2003) The trypanosomiases. Lancet 362, 1469-1480
3Stuart, K. et al. (2008) Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation 118, 1301-1310
4Barrett, M.P. (2006) The rise and fall of sleeping sickness. Lancet 367, 1377-1378
5Matovu, E. et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Molecular and Biochemical Parasitology 117, 73-81
6Checchi, F. et al. (2007) Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Neglected Tropical Diseases 1, e64
7Priotto, G. et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clinical Trials 1, e39
8Priotto, G. et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374, 56-64
9Docampo, R. and Moreno, S.N. (2003) Current chemotherapy of human African trypanosomiasis. Parasitology Research 90, S10-13
10Nok, A.J. (2003) Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitology Research 90, 71-79
11Legros, D. et al. (2002) Treatment of human African trypanosomiasis–present situation and needs for research and development. Lancet Infectious Diseases 2, 437-440
12Spinks, A. (1948) The persistence in the blood stream of some compounds related to suramin. Biochemical Journal 42, 109-116
13Fairlamb, A.H. and Bowman, I.B. (1980) Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. Molecular and Biochemical Parasitology 1, 315-333
14Coppens, I. et al. (1987) Receptor-mediated endocytosis in the bloodstream form of Trypanosoma brucei. Journal of Protozoology 34, 465-473
15Vansterkenburg, E.L. et al. (1993) The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Tropica 54, 237-250
16Pal, A., Hall, B.S. and Field, M.C. (2002) Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. Molecular and Biochemical Parasitology 122, 217-221
17Scott, A.G., Tait, A. and Turner, C.M. (1996) Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin. Acta Tropica 60, 251-262
18Mutugi, M.W., Boid, R. and Luckins, A.G. (1994) Experimental induction of suramin-resistance in cloned and uncloned stocks of Trypanosoma evansi using immunosuppressed and immunocompetent mice. Tropical Medicine and Parasitology 45, 232-236
19Misset, O. and Opperdoes, F.R. (1987) The phosphoglycerate kinases from Trypanosoma brucei. A comparison of the glycosomal and the cytosolic isoenzymes and their sensitivity towards suramin. European Journal of Biochemistry 162, 493-500
20Willson, M. et al. (1993) Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Molecular and Biochemical Parasitology 59, 201-210
21Conte, J.E. Jr, Upton, R.A. and Lin, E.T. (1987) Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. Journal of Infectious Diseases 156, 885-890
22Berger, B.J. et al. (1992) Primary and secondary metabolism of pentamidine by rats. Antimicrobial Agents and Chemotherapy 36, 1825-1831
23Berger, B.J. and Fairlamb, A.H. (1993) Cytochrome P450 in trypanosomatids. Biochemical Pharmacology 46, 149-157
24Sanderson, L. et al. (2009) Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. Journal of Pharmacology and Experimental Therapeutics 329, 967-977
25Carter, N.S., Berger, B.J. and Fairlamb, A.H. (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. Journal of Biological Chemistry 270, 28153-28157
26de Koning, H.P., and Jarvis, S.M. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Tropica 80, 245-250
27Berger, B.J., Carter, N.S. and Fairlamb, A.H. (1995) Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 69, 289-298
28Matovu, E. et al. (2003) Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryotic Cell 2, 1003-1008
29De Koning, H.P. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Molecular Pharmacology 59, 586-592
30Bridges, D.J. et al. (2007) Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Molecular Pharmacology 71, 1098-1108
31Wilson, W.D. et al. (2008) Antiparasitic compounds that target DNA. Biochimie 90, 999-1014
32Mathis, A.M. et al. (2006) Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrobial Agents and Chemotherapy 50, 2185-2191
33Shapiro, T.A. and Englund, P.T. (1990) Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proceedings of the National Academy of Sciences of the United States of America 87, 950-954
34Wang, C.C. (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annual Review of Pharmacology and Toxicology 35, 93-127
35Bitonti, A.J., Dumont, J.A. and McCann, P.P. (1986) Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochemical Journal 237, 685-689
36Benaim, G. et al. (1993) A calmodulin-stimulated Ca2+ pump in plasma-membrane vesicles from Trypanosoma brucei; selective inhibition by pentamidine. Biochemical Journal 296, 759-763
37Vercesi, A.E. and Docampo, R. (1992) Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochemical Journal 284, 463-467
38Moreno, S.N. (1996) Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Archives of Biochemistry and Biophysics 326, 15-20
39Friedheim, E.A. (1949) Mel B in the treatment of human trypanosomiasis. American Journal of Tropical Medicine and Hygiene 29, 173-180
40Enanga, B. et al. (2002) Sleeping sickness and the brain. Cellular and Molecular Life Sciences 59, 845-858
41Blum, J. and Burri, C. (2002) Treatment of late stage sleeping sickness caused by T.b. gambiense: a new approach to the use of an old drug. Swiss Medical Weekly 132, 51-56
42Burri, C. et al. (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39, 225-234
43Carter, N.S. and Fairlamb, A.H. (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361, 173-176
44Maser, P. et al. (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285, 242-244
45Barrett, M.P. and Fairlamb, A.H. (1999) The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitology Today 15, 136-140
46Tye, C.K. et al. (1998) An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorganic and Medicinal Chemistry Letters 8, 811-816
47de Koning, H.P. and Jarvis, S.M. (1999) Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs. Molecular Pharmacology 56, 1162-1170
48de Koning, H.P. (2001) Transporters in African trypanosomes: role in drug action and resistance. International Journal of Parasitology 31, 512-522
49Baliani, A. et al. (2005) Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. Journal of Medicinal Chemistry 48, 5570-5579
50Stewart, M.L. et al. (2004) Trypanocidal activity of melamine-based nitroheterocycles. Antimicrobial Agents and Chemotherapy 48, 1733-1738
51Baliani, A. et al. (2009) Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites. Organic and Biomolecular Chemistry 7, 1154-1166
52Chollet, C. et al. (2009) Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. Bioorganic and Medicinal Chemistry 17, 2512-2523
53Fairlamb, A.H. et al. (1992) Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Molecular and Biochemical Parasitology 53, 213-222
54de Koning, H.P. (2008) Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends in Parasitology 24, 345-349
55Van Schaftingen, E., Opperdoes, F.R. and Hers, H.G. (1987) Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic intermediates in Trypanosoma brucei. European Journal of Biochemistry 166, 653-661
56Hanau, S. et al. (1996) 6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs. European Journal of Biochemistry 240, 592-599
57Fairlamb, A.H. et al. (1985) Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 1485-1487
58Fairlamb, A.H., Henderson, G.B. and Cerami, A. (1989) Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 86, 2607-2611
59Cunningham, M.L., Zvelebil, M.J. and Fairlamb, A.H. (1994) Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. European Journal of Biochemistry 221, 285-295
60Krieger, S. et al. (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Molecular Microbiology 35, 542-552
61Sauvage, V. et al. The role of ATP-Binding Cassette (ABC) proteins in protozoan parasites. Molecular and Biochemical Parasitology 167, 81-94
62Shahi, S.K., Krauth-Siegel, R.L. and Clayton, C.E. (2002) Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Molecular Microbiology 43, 1129-1138
63Alibu, V.P. et al. (2006) The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Molecular and Biochemical Parasitology 146, 38-44
64Bacchi, C.J. et al. (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210, 332-334
65Robays, J. et al. (2008) Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. Tropical Medicine and International Health 13, 265-271
66Sanderson, L. et al. (2008) The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. Journal of Neurochemistry 107, 1136-1146
67Balasegaram, M. et al. (2009) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Transactions of the Royal Society of Tropical Medicine and Hygiene 103, 280-290
68Politi, C. et al. (1995) Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Health Eeconomics 4, 273-287
69Chappuis, F. et al. (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clinical Infectious Diseases 41, 748-751
70Bellofatto, V. et al. (1987) Biochemical changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Molecular and Biochemical Parasitology 25, 227-238
71Erwin, B.G. and Pegg, A.E. (1982) Uptake of alpha-difluoromethylornithine by mouse fibroblasts. Biochemical Pharmacology 31, 2820-2823
72Bitonti, A.J. et al. (1986) Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochemical Pharmacology 35, 351-354
73Phillips, M.A. and Wang, C.C. (1987) A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Molecular and Biochemical Parasitology 22, 9-17
74Willert, E.K. and Phillips, M.A. (2008) Regulated expression of an essential allosteric activator of polyamine biosynthesis in African trypanosomes. PLoS Pathogens 4, e1000183
75Phillips, M.A., Coffino, P. and Wang, C.C. (1987) Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. Journal of Biological Chemistry 262, 8721-8727
76Ghoda, L. et al. (1990) Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. Journal of Biological Chemistry 265, 11823-11826
77Tabor, C.W. and Tabor, H. (1984) Polyamines. Annual Review of Biochemistry 53, 749-790
78Iten, M. et al. (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrobial Agents and Chemotherapy 41, 1922-1925
79Schofield, C.J., Jannin, J. and Salvatella, R. (2006) The future of Chagas disease control. Trends in Parasitology 22, 583-588
80Bern, C. et al. (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. Journal of the American Medical Association 298, 2171-2181
81Diazgranados, C.A. et al. (2009) Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infectious Diseases 9, 324-330
82Dias, J.C., Silveira, A.C. and Schofield, C.J. (2002) The impact of Chagas disease control in Latin America: a review. Memorias do Instituto Oswaldo Cruz 97, 603-612
83Rodriques Coura, J. and de Castro, S.L. (2002) A critical review on Chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz 97, 3-24
84Gorla, N.B. et al. (1989) Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutation Research 224, 263-267
85Ferreira, R.C., Schwarz, U. and Ferreira, L.C. (1988) Activation of anti-Trypanosoma cruzi drugs to genotoxic metabolites promoted by mammalian microsomal enzymes. Mutation Research 204, 577-583
86Kalil, J. and Cunha-Neto, E. (1996) Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last? Parasitology Today 12, 396-399
87Tarleton, R.L., Zhang, L. and Downs, M.O. (1997) “Autoimmune rejection” of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue. Proceedings of the National Academy of Sciences of the United States of America 94, 3932-3937
88Tarleton, R.L. and Zhang, L. (1999) Chagas disease etiology: autoimmunity or parasite persistence? Parasitology Today 15, 94-99
89Tarleton, R.L. (2003) Chagas disease: a role for autoimmunity? Trends in Parasitology 19, 447-451
90Garcia, S. et al. (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49, 1521-1528
91Bustamante, J.M., Bixby, L.M. and Tarleton, R.L. (2008) Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nature Medicine 14, 542-550
92Walton, M.I. and Workman, P. (1987) Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology 36, 887-896
93Montalto de Mecca, M., Diaz, E.G. and Castro, J.A. (2002) Nifurtimox biotransformation to reactive metabolites or nitrite in liver subcellular fractions and model systems. Toxicology Letters 136, 1-8
94Mecca, M.M. et al. (2008) Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects. Memorias do Instituto Oswaldo Cruz 103, 549-553
95Raether, W. and Hanel, H. (2003) Nitroheterocyclic drugs with broad spectrum activity. Parasitology Research 90, S19-39
96Docampo, R. (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chemico-Biological Interactions 73, 1-27
97Docampo, R. et al. (1981) Generation of free radicals induced by nifurtimox in mammalian tissues. Journal of Biological Chemistry 256, 10930-10933
98Viode, C. et al. (1999) Enzymatic reduction studies of nitroheterocycles. Biochemical Pharmacology 57, 549-557
99Henderson, G.B. et al. (1988) “Subversive” substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proceedings of the National Academy of Sciences of the United States of America 85, 5374-5378
100Blumenstiel, K. et al. (1999) Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochemical Pharmacology 58, 1791-1799
101Boveris, A. et al. (1980) Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochemical Journal 188, 643-648
102Fairlamb, A.H. and Cerami, A. (1992) Metabolism and functions of trypanothione in the Kinetoplastida. Annual Review of Microbiology 46, 695-729
103Flohe, L., Hecht, H.J. and Steinert, P. (1999) Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radical Biology and Medicine 27, 966-984
104Wilkinson, S.R. et al. (2002) Trypanosoma cruzi expresses a plant-like ascorbate-dependent hemoperoxidase localized to the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America 99, 13453-13458
105Wilkinson, S.R. and Kelly, J.M. (2003) The role of glutathione peroxidases in trypanosomatids. Biological Chemistry 384, 517-525
106Irigoín, F. et al. (2008) Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification. Free Radical Biology and Medicine 45, 733-742
107Prathalingham, S.R. et al. (2007) Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrobial Agents and Chemotherapy 51, 755-758
108Wilkinson, S.R. et al. (2000) Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi. Journal of Biological Chemistry 275, 8220-8225
109Wilkinson, S.R. et al. (2002) The Trypanosoma cruzi enzyme TcGPXI is a glycosomal peroxidase and can be linked to trypanothione reduction by glutathione or tryparedoxin. Journal of Biological Chemistry 277, 17062-17071
110Wilkinson, S.R. et al. (2002) TcGPXII, a glutathione-dependent Trypanosoma cruzi peroxidase with substrate specificity restricted to fatty acid and phospholipid hydroperoxides, is localized to the endoplasmic reticulum. Biochemical Journal 364, 787-794
111Wilkinson, S.R. et al. (2003) RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the bloodstream form of the African trypanosome. Journal of Biological Chemistry 278, 31640-13646
112Wilkinson, S.R. et al. (2006) Functional characterisation of the iron superoxide dismutase gene repertoire in Trypanosoma brucei. Free Radical Biology and Medicine 40, 198-209
113Kelly, J.M. et al. (1993) Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. European Journal of Biochemistry 218, 29-37
114Peterson, F.J. et al. (1979) Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. Journal of Biological Chemistry 254, 4009-4014
115Roldan, M.D. et al. (2008) Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiology Reviews 32, 474-500
116McCalla, D.R., Reuvers, A. and Kaiser, C. (1971) Breakage of bacterial DNA by nitrofuran derivatives. Cancer Research 31, 2184-2188
117Streeter, A.J. and Hoener, B.A. (1988) Evidence for the involvement of a nitrenium ion in the covalent binding of nitrofurazone to DNA. Pharmaceutical Research 5, 434-436
118Maya, J.D. et al. (1997) Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Molecular and Biochemical Parasitology 86, 101-106
119Kubata, B.K. et al. (2002) A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. Journal of Experimental Medicine 196, 1241-1251
120Wilkinson, S.R. et al. (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America 105, 5022-5027
121Nozaki, T., Engel, J.C. and Dvorak, J.A. (1996) Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi. American Journal of Tropical Medicine and Hygiene 55, 111-117
122Murta, S.M. and Romanha, A.J. (1998) In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitology 116, 165-171
123Nogueira, F.B. et al. (2006) Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Tropica 100, 119-132
124Murta, S.M. et al. (2006) Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Molecular and Biochemical Parasitology 146, 151-162
125Murta, S.M. et al. (2008) Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Tropica 107, 59-65
126Andrade, H.M. et al. (2008) Proteomic analysis of Trypanosoma cruzi resistance to Benznidazole. Journal of Proteome Research 7, 2357-2367
127Rego, J.V. et al. (2008) Trypanosoma cruzi: characterisation of the gene encoding tyrosine aminotransferase in benznidazole-resistant and susceptible populations. Experimental Parasitology 118, 111-117
128Campos, F.M. et al. (2009) Characterization of a gene encoding alcohol dehydrogenase in benznidazole-susceptible and-resistant populations of Trypanosoma cruzi. Acta Tropica 111, 56-63
129Nogueira, F.B. et al. (2009) Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Parasitology Research 104, 835-844
130Portal, P. et al. (2008) Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi suggested role on drug resistance. Molecular and Biochemical Parasitology 160, 42-51
131El-Sayed, N.M. et al. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science 309, 404-409
132Berriman, M. et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309, 416-422
133Meissner, M., Agop-Nersesian, C. and Sullivan, W.J. Jr, (2007) Molecular tools for analysis of gene function in parasitic microorganisms. Applied Microbiology and Biotechnology 75, 963-975
134Motyka, S.A. and Englund, P.T. (2004) RNA interference for analysis of gene function in trypanosomatids. Current Opinion in Microbiology 7, 362-368
135Furlong, S.T. (1989) Sterols of parasitic protozoa and helminths. Experimental Parasitology 68, 482-485
136Buckner, F. et al. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America 100, 15149-15153
137Buckner, F.S. et al. (2003) Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Molecular and Biochemical Parasitology 132, 75-81
138Buckner, F.S. et al. (2001) Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrobial Agents and Chemotherapy 45, 1210-1205
139Urbina, J.A. et al. (2002) Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Molecular and Biochemical Parasitology 125, 35-45
140Lepesheva, G.I. et al. (2007) Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chemistry and Biology 14, 1283-1293
141Chen, C.K. et al. (2009) Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit. PLoS Neglected Tropical Diseases 3, e372
142Konkle, M.E. et al. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. Journal of Medicinal Chemistry 52, 2846-2853
143Coppens, I. and Courtoy, P.J. (2000) The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annual Review of Microbiology 54, 129-156
144Urbina, J.A. and Docampo, R. (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends in Parasitology 19, 495-501
145Roberts, C.W. et al. (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Molecular and Biochemical Parasitology 126, 129-142
146Urbina, J.A. (2009) Ergosterol biosynthesis and drug development for Chagas disease. Memorias do Instituto Oswaldo Cruz 104, 311-318
147Hucke, O. et al. (2005) The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. Journal of Medicinal Chemistry 48, 5415-5418
148Suryadevara, P.K. et al. (2009) Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. Journal of Medicinal Chemistry 52, 3703-3715
149Kraus, J.M. et al. (2009) Rational modification of a candidate cancer drug for use against Chagas disease. Journal of Medicinal Chemistry 52, 1639-1647
150McKerrow, J.H. et al. (2009) Two approaches to discovering and developing new drugs for Chagas disease. Memorias do Instituto Oswaldo Cruz 104, 263-269
151Molina, J. et al. (2000) In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. Journal of Antimicrobial Chemotherapy 46, 137-140
152Urbina, J.A. et al. (2003) Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. International Journal of Antimicrobial Agents 21, 39-48
153Urbina, J.A. et al. (1988) Synergistic effects of ketoconazole and SF-86327 on the proliferation of epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Annals of the New York Academy of Sciences 544, 357-358
154Gerpe, A. et al. (2008) Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorganic and Medicinal Chemistry 16, 569-577
155Maldonado, R.A. et al. (1993) Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrobial Agents and Chemotherapy 37, 1353-1359
156Hinshaw, J.C. et al. (2003) Oxidosqualene cyclase inhibitors as antimicrobial agents. Journal of Medicinal Chemistry 46, 4240-4243
157Urbina, J.A. et al. (1995) Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Molecular and Biochemical Parasitology 73, 199-210
158Urbina, J.A. et al. (1996) Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42, 294-307
159Magaraci, F. et al. (2003) Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. Journal of Medicinal Chemistry 46, 4714-4727
160Lorente, S.O. et al. (2004) Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrobial Agents and Chemotherapy 48, 2937-2950
161Gros, L. et al. (2006) Evaluation of azasterols as anti-parasitics. Journal of Medicinal Chemistry 49, 6094-6103
162Gigante, F. et al. (2009) SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorganic and Medicinal Chemistry 17, 5950-5961
163Gros, L. et al. (2006) New azasterols against Trypanosoma brucei: role of 24-sterol methyltransferase in inhibitor action. Antimicrobial Agents and Chemotherapy 50, 2595-2601
164Cazzulo, J.J. et al. (1989) Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Molecular and Biochemical Parasitology 33, 33-41
165Murta, A.C. et al. (1990) Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Molecular and Biochemical Parasitology 43, 27-38
166Eakin, A.E. et al. (1992) The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. Journal of Biological Chemistry 267, 7411-7420
167Caffrey, C.R. et al. (2001) Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Molecular and Biochemical Parasitology 118, 61-73
168Lima, A.P. et al. (1994) Identification of new cysteine protease gene isoforms in Trypanosoma cruzi. Molecular and Biochemical Parasitology 67, 333-338
169Garcia, M.P. et al. (1998) Characterisation of a Trypanosoma cruzi acidic 30 kDa cysteine protease. Molecular and Biochemical Parasitology 91, 263-272
170Nobrega, O.T. et al. (1998) Cloning and sequencing of tccb, a gene encoding a Trypanosoma cruzi cathepsin B-like protease. Molecular and Biochemical Parasitology 97, 235-240
171Mackey, Z.B. et al. (2004) A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei. Journal of Biological Chemistry 279, 48426-48433
172Caffrey, C.R. and Steverding, D. (2009) Kinetoplastid papain-like cysteine peptidases. Molecular and Biochemical Parasitology 167, 12-19
173McKerrow, J.H., McGrath, M.E. and Engel, J.C. (1995) The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitology Today 11, 279-282
174Engel, J.C. et al. (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. Journal of Experimental Medicine 188, 725-734
175Du, X. et al. (2000) Aryl ureas represent a new class of anti-trypanosomal agents. Chemistry and Biology 7, 733-742
176Roush, W.R. et al. (2001) Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorganic and Medicinal Chemistry Letters 11, 2759-2762
177Du, X. et al. (2002) Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. Journal of Medicinal Chemistry 45, 2695-2707
178Greenbaum, D.C. et al. (2004) Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. Journal of Medicinal Chemistry 47, 3212-3219
179Nkemgu, N.J. et al. (2003) Improved trypanocidal activities of cathepsin L inhibitors. International Journal of Antimicrobial Agents 22, 155-1559
180Doyle, P.S. et al. (2007) A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrobial Agents and Chemotherapy 51, 3932-3939
181Chen, Y.T. et al. (2008) Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorganic and Medicinal Chemistry Letters 18, 5860-5863
182Mallari, J.P. et al. (2008) Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorganic and Medicinal Chemistry Letters 18, 2883-2885
183Mallari, J.P. et al. (2008) Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. Journal of Medicinal Chemistry 51, 545-552
184McGrath, M.E. et al. (1995) The crystal structure of cruzain: a therapeutic target for Chagas' disease. Journal of Molecular Biology 247, 251-259
185Eakin, A.E. et al. (1993) Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. Journal of Biological Chemistry 268, 6115-6118
186Huang, L., Brinen, L.S. and Ellman, J.A. (2003) Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Bioorganic and Medicinal Chemistry 11, 21-29
187Choe, Y. et al. (2005) Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorganic and Medicinal Chemistry 13, 2141-2156
188Kerr, I.D. et al. (2009) Vinyl sulfones as antiparasitic agents: A structural basis for drug design. Journal of Biological Chemistry 284, 25697-25703
189Tomas, A.M., Miles, M.A. and Kelly, J.M. (1997) Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. European Journal of Biochemistry 244, 596-603
190Abdulla, M.H. et al. (2008) RNA interference of Trypanosoma brucei cathepsin B and L affects disease progression in a mouse model. PLoS Neglected Tropical Diseases 2, e298
191Krauth-Siegel, R.L. and Comini, M.A. (2008) Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochimica et Biophysica Acta 1780, 1236-1248
192Krauth-Siegel, R.L. and Inhoff, O. (2003) Parasite-specific trypanothione reductase as a drug target molecule. Parasitology Research 90, S77-85
193Jaeger, T. and Flohe, L. (2006) The thiol-based redox networks of pathogens: unexploited targets in the search for new drugs. Biofactors 27, 109-120
194Comini, M.A., Krauth-Siegel, R.L. and Flohe, L. (2007) Depletion of the thioredoxin homologue tryparedoxin impairs antioxidative defence in African trypanosomes. Biochemical Journal 402, 43-49
195Comini, M.A. et al. (2004) Valdiation of Trypanosoma brucei trypanothione synthetase as drug target. Free Radical Biology and Medicine 36, 1289-1302
196Ariyanayagam, M.R. et al. (2005) Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochemical Journal 391, 425-432
197Wyllie, S. et al. (2009) Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Molecular Microbiology Jun 24; [Epub ahead of print]
198Jockers-Scherubl, M.C., Schirmer, R.H. and Krauth-Siegel, R.L. (1989) Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds. European Journal of Biochemistry 180, 267-272
199Fournet, A. et al. (1998) Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase. Journal of Enzyme Inhibition 13, 1-9
200Zani, C.L. et al. (1997) Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiopen-4,9-quinones. Bioorganic and Medicinal Chemistry 5, 2185-2192
201Bond, C.S. et al. (1999) Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure 7, 81-89
202Gallwitz, H. et al. (1999) Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. Journal of Medicinal Chemistry 42, 364-372
203Fournet, A. et al. (2000) Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model. International Journal of Antimicrobial Agents 13, 189-195
204Salmon-Chemin, L. et al. (2000) Parallel synthesis of a library of 1,4-naphthoquinones and automated screening of potential inhibitors of trypanothione reductase from Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters 10, 631-635
205Salmon-Chemin, L. et al. (2001) 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. Journal of Medicinal Chemistry 44, 548-565
206Zani, C.L. and Fairlamb, A.H. (2003) 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Memorias do Instituto Oswaldo Cruz 98, 565-568
207Hamilton, C.J. et al. (2003) Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochemical Journal 369, 529-537
208Hamilton, C.J. et al. (2003) Benzofuranyl 3,5-bis-polyamine derivatives as time-dependent inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry 11, 3683-3693
209Hamilton, C.J. et al. (2006) Time-dependent inhibitors of trypanothione reductase: analogues of the spermidine alkaloid lunarine and related natural products. Bioorganic and Medicinal Chemistry 14, 2266-2278
210Stump, B. et al. (2007) Betraying the parasite's redox system: diaryl sulfide-based inhibitors of trypanothione reductase: subversive substrates and antitrypanosomal properties. ChemMedChem 2, 1708-1712
211Martyn, D.C. et al. (2007) High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorganic and Medicinal Chemistry Letters 17, 1280-1283
212Czechowicz, J.A. et al. (2007) The synthesis and inhibitory activity of dethiotrypanothione and analogues against trypanothione reductase. Journal of Organic Chemistry 72, 3689-3693
213Stump, B. et al. (2009) Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines. Chembiochem 10, 79-83
214Stump, B. et al. (2008) Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities. Organic and Biomolecular Chemistry 6, 3935-3947
215Holloway, G.A. et al. (2009) Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity. Antimicrobial Agents and Chemotherapy 53, 2824-2833
216Holloway, G.A. et al. (2007) Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorganic and Medicinal Chemistry Letters 17, 1422-1427
217Cavalli, A. et al. (2009) Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry Letters 19, 3031-3035
218Richardson, J.L. et al. (2009) Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. ChemMedChem 4, 1333-1340
219Patterson, S. et al. (2009) Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase. ChemMedChem 4, 1341-1353
220Zhang, Y. et al. (1993) Trypanosoma cruzi trypanothione reductase. Crystallization, unit cell dimensions and structure solution. Journal of Molecular Biology 232, 1217-1220
221Lantwin, C.B. et al. (1994) The structure of Trypanosoma cruzi trypanothione reductase in the oxidized and NADPH reduced state. Proteins 18, 161-173
222Jacoby, E.M. et al. (1996) Crystal structure of the Trypanosoma cruzi trypanothione reductase.mepacrine complex. Proteins 24, 73-80
223Zhang, Y. et al. (1996) The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. Protein Science 5, 52-61
224Saravanamuthu, A. et al. (2004) Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design. Journal of Biological Chemistry 279, 29493-29500
225Meiering, S. et al. (2005) Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis. Journal of Medicinal Chemistry 48, 4793-4802
226Ogungbe, I.V. and Setzer, W.N. (2009) Comparative molecular docking of antitrypanosomal natural products into multiple Trypanosoma brucei drug targets. Molecules 14, 1513-1536
227Alphey, M.S. et al. (2003) Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei: photoreduction of the redox disulfide using synchrotron radiation and evidence for a conformational switch implicated in function. Journal of Biological Chemistry 278, 25919-25925
228Alphey, M.S., Konig, J. and Fairlamb, A.H. (2008) Structural and mechanistic insights into type II trypanosomatid tryparedoxin-dependent peroxidases. Biochemical Journal 414, 375-381
229Melchers, J. et al. (2008) Structural basis for a distinct catalytic mechanism in Trypanosoma brucei tryparedoxin peroxidase. Journal of Biological Chemistry 283, 30401-30411
230Bitonti, A.J., Kelly, S.E. and McCann, P.P. (1984) Characterization of spermidine synthase from Trypanosoma brucei brucei. Molecular and Biochemical Parasitology 13, 21-28
231Tekwani, B.L., Bacchi, C.J. and Pegg, A.E. (1992) Putrescine activated S-adenosylmethionine decarboxylase from Trypanosoma brucei brucei. Molecular and Cellular Biochemistry 117, 53-61
232Yarlett, N. et al. (1993) S-adenosylmethionine synthetase in bloodstream Trypanosoma brucei. Biochimica et Biophysica Acta 1181, 68-76
233Taylor, M.C. et al. (2008) Validation of spermidine synthase as a drug target in African trypanosomes. Biochemical Journal 409, 563-569
234Huynh, T.T. et al. (2003) Gene knockdown of gamma-glutamylcysteine synthetase by RNAi in the parasitic protozoa Trypanosoma brucei demonstrates that it is an essential enzyme. Journal of Biological Chemistry 278, 39794-39800
235Xiao, Y., McCloskey, D.E. and Phillips, M.A. (2009) RNA interference-mediated silencing of ornithine decarboxylase and spermidine synthase genes in Trypanosoma brucei provides insight into regulation of polyamine biosynthesis. Eukaryotic Cell 8, 747-755
236Tekwani, B.L. et al. (1992) Irreversible inhibition of S-adenosylmethionine decarboxylase of Trypanosoma brucei brucei by S-adenosylmethionine analogues. Biochemical Pharmacology 44, 905-911
237Guo, J. et al. (1995) S-(5′-deoxy-5′-adenosyl)-1-aminoxy-4-(methylsulfonio)-2-cyclopentene (AdoMao): an irreversible inhibitor of S-adenosylmethionine decarboxylase with potent in vitro antitrypanosomal activity. Journal of Medicinal Chemistry 38, 1770-1777
238Brun, R. et al. (1996) In vitro trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrobial Agents and Chemotherapy 40, 1442-1447
239Marasco, C.J. Jr et al. , (2002) Synthesis and evaluation of analogues of 5′-([(Z)-4-amino-2-butenyl]methylamino)-5′-deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity. Journal of Medicinal Chemistry 45, 5112-5122
240Hirth, B. et al. (2009) Discovery of new S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis (HAT). Bioorganic and Medicinal Chemistry Letters 19, 2916-2919
241Bitonti, A.J. et al. (1990) Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrobial Agents and Chemotherapy 34, 1485-1490
242Bacchi, C.J. et al. (1992) Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrobial Agents and Chemotherapy 36, 2736-2740
243Bacchi, C.J. et al. (1996) In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrobial Agents and Chemotherapy 40, 1448-1453
244Byers, T.L. et al. (1991) Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine. Biochemical Journal 274, 527-533
245Bacchi, C.J. et al. (2009) Trypanocidal activity of 8-methyl-5′-{[(Z)-4-aminobut-2-enyl]-(methylamino)}adenosine (Genz-644131), an adenosylmethionine decarboxylase inhibitor. Antimicrobial Agents and Chemotherapy 53, 3269-3272
246Barker, R.H. Jr et al. (2009) Novel S-adenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrobial Agents and Chemotherapy 53, 2052-2058
247Priotto, G. et al. (2007) Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clinical Infectious Disease 45, 1435-1442
248Rane, L., Rane, D. and Kinnamon, K.E. (1976) Screening large numbers of compounds in a model based on mortality of Trypanosoma rhodesiense infected mice. American Journal of Tropical Medicine and Hygiene 25, 395-400
249Das, B.P. and Boykin, D.W. (1977) Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. Journal of Medicinal Chemistry 20, 531-536
250Ansede, J.H. et al. (2005) In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica 35, 211-226
251Conte, J.E. Jr et al. (1986) Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. Journal of Infectious Diseases 154, 923-929
252Burri, C. and Brun, R. (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitology Research 90, S49-52
253Paulos, C. et al. (1989) Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology 27, 454-457
254Raaflaub, J. and Ziegler, W.H. (1979) Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 29, 1611-1614

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed